Enrollment in SCORE Trial Discontinued

Long Term Follow-Up to Continue



Apr 20, 2001, 01:00 ET from Boston Scientific Corporation

    NATICK, Mass., April 20 /PRNewswire Interactive News Release/ --
 Boston Scientific Corporation (NYSE:   BSX) today announced the decision to
 discontinue further enrollment in the SCORE clinical trial and to continue
 collection of follow-up data on the current study group.  The SCORE trial was
 initiated in February 2000 by Quanam Medical Corporation, which Boston
 Scientific recently acquired to broaden its drug-delivery portfolio and
 polymers expertise.
     The SCORE trial is a European, multi-center, randomized study designed to
 compare the safety and efficacy of Quanam's QuaDS-QP2 drug-delivery stent to
 that of bare metal stents in de novo coronary lesions.  Despite encouraging
 interim results on the ability of this technology to reduce restenosis, the
 rate of major adverse cardiac events was unacceptable, and enrollment in the
 study has been discontinued.  The decision is based on the outcome of a
 previously announced review of the trial results by a panel of clinical
 experts.
     Early data from the trial suggests that patients not impacted by an
 adverse event may show promise for improved efficacy.  The Company will
 continue to evaluate the benefit of this pioneering technology and will
 collect six-month data in the current enrolled study group.
     The clinical trial was compromised by protocol violations such as use of
 the stent outside the study design and lack of medication compliance.  These
 protocol violations are likely related to adverse effects.
     "We were aware that enrollment in the trial had been suspended prior to
 our acquisition of Quanam," said Kshitij Mohan, Ph.D., Senior Vice President
 and Chief Technology Officer of Boston Scientific.  "However, we are
 encouraged by the promise of this technology to reduce restenosis
 significantly and hope to use the follow-up data to evaluate it in the longer
 term.  We are examining opportunities for conducting other well-controlled
 clinical trials on this technology and studying the roles of different drugs
 and polymers in the treatment of coronary artery disease."
     Boston Scientific is a worldwide developer, manufacturer and marketer of
 medical devices whose products are used in a broad range of interventional
 medical specialties.
 
     This press release contains forward-looking statements.  The Company
 wishes to caution the reader of this press release that actual results may
 differ from those discussed in the forward-looking statements and may be
 affected by, among other things, risks associated with clinical trials, the
 regulatory approval process, commercialization of new products, competitive
 product offerings and other factors described in the Company's filings with
 the Securities and Exchange Commission.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X70730646
 
 

SOURCE Boston Scientific Corporation
    NATICK, Mass., April 20 /PRNewswire Interactive News Release/ --
 Boston Scientific Corporation (NYSE:   BSX) today announced the decision to
 discontinue further enrollment in the SCORE clinical trial and to continue
 collection of follow-up data on the current study group.  The SCORE trial was
 initiated in February 2000 by Quanam Medical Corporation, which Boston
 Scientific recently acquired to broaden its drug-delivery portfolio and
 polymers expertise.
     The SCORE trial is a European, multi-center, randomized study designed to
 compare the safety and efficacy of Quanam's QuaDS-QP2 drug-delivery stent to
 that of bare metal stents in de novo coronary lesions.  Despite encouraging
 interim results on the ability of this technology to reduce restenosis, the
 rate of major adverse cardiac events was unacceptable, and enrollment in the
 study has been discontinued.  The decision is based on the outcome of a
 previously announced review of the trial results by a panel of clinical
 experts.
     Early data from the trial suggests that patients not impacted by an
 adverse event may show promise for improved efficacy.  The Company will
 continue to evaluate the benefit of this pioneering technology and will
 collect six-month data in the current enrolled study group.
     The clinical trial was compromised by protocol violations such as use of
 the stent outside the study design and lack of medication compliance.  These
 protocol violations are likely related to adverse effects.
     "We were aware that enrollment in the trial had been suspended prior to
 our acquisition of Quanam," said Kshitij Mohan, Ph.D., Senior Vice President
 and Chief Technology Officer of Boston Scientific.  "However, we are
 encouraged by the promise of this technology to reduce restenosis
 significantly and hope to use the follow-up data to evaluate it in the longer
 term.  We are examining opportunities for conducting other well-controlled
 clinical trials on this technology and studying the roles of different drugs
 and polymers in the treatment of coronary artery disease."
     Boston Scientific is a worldwide developer, manufacturer and marketer of
 medical devices whose products are used in a broad range of interventional
 medical specialties.
 
     This press release contains forward-looking statements.  The Company
 wishes to caution the reader of this press release that actual results may
 differ from those discussed in the forward-looking statements and may be
 affected by, among other things, risks associated with clinical trials, the
 regulatory approval process, commercialization of new products, competitive
 product offerings and other factors described in the Company's filings with
 the Securities and Exchange Commission.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X70730646
 
 SOURCE  Boston Scientific Corporation